Biofrontera Inc. (BFRIW) stock
BFRIWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRI
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30
$0.00+0.00 (0.00%)
Close on Oct 30, 2026Market cap $12.96MP/E –Yield –
Biofrontera operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Biofrontera's operating income for the twelve months ending Jun 30, 2026 was -$6.56M. For fiscal 2025 it was -$11.35M. The highest annual figure on record is -$9.61M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.35M | – |
| FY2024 | Dec 31, 2024 | -$17.21M | – |
| FY2023 | Dec 31, 2023 | -$22.68M | – |
| FY2022 | Dec 31, 2022 | -$18.58M | – |
| FY2021 | Dec 31, 2021 | -$25.20M | – |
| FY2020 | Dec 31, 2020 | -$9.61M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$524.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.32M | – |
| Q4 FY2025 | Dec 31, 2025 | $4.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.08M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.55M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.71M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.96M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.07M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.47M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.87M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.62M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.70M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.49M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.62M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.64M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.21M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.11M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.88M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.11M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.69M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.53M | – |
| Q4 FY2020 | Dec 31, 2020 | -$188.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.34M | – |